Novartis announced that first results of the RESTORE Phase III study show that ranibizumab is significantly more effective than laser treatment, the current standard of care, at treating visual impairment due to diabetic macular edema (DME), a serious complication of diabetes. The one year results show that 37% of patients treated with ranibizumab 0.5 mg alone, and 43% of those treated with ranibizumab...




